Outcome of acute myelogenous leukemia in 41 patients treated with idarubicin: the prognosis of t(8;21) cases

DOI Web Site PubMed 1 Citations 19 References
  • MATSUMOTO Yuko
    Department of Hematology, Jichi Medical School Division of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
  • MORI Masaki
    Department of Hematology, Jichi Medical School
  • OHTSUKI Tetsuya
    Department of Hematology, Jichi Medical School
  • MUROI Kazuo
    Department of Hematology, Jichi Medical School
  • HATAKE Kiyohiko
    Department of Hematology, Jichi Medical School Division of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
  • KOMATSU Norio
    Department of Hematology, Jichi Medical School
  • OZAWA Keiya
    Department of Hematology, Jichi Medical School

Bibliographic Information

Other Title
  • イダルビシンを用いて寛解導入療法を行った初発急性骨髄性白血病自験例41例の解析：特にt(8;21)を有するM2の長期予後について
  • 臨床研究 イダルビシンを用いて寛解導入療法を行った初発急性骨髄性白血病自験例41例の解析:特にt(8:21)を有するM2の長期予後について
  • リンショウ ケンキュウ イダルビシン オ モチイテ カンカイドウニュウ リョウホウ オ オコナッタ ショハツ キュウセイ コツズイセイ ハッケツビョウジケンレイ 41レイ ノ カイセキ トクニ t 8 21 オ ユウスル M2 ノ チョウキ ヨゴ ニ ツイテ

Search this article

Description

Idarubicin (IDR) has been used as the main drug in induction chemotherapy for acute myelogenous leukemia (AML) in the USA and Europe. Between May 1995 and October 1998, we treated 41 cases of fresh AML using IDR induction chemotherapy and analyzed the clinical course, remission rate, relapse rate and prognosis. The results obtained in these cases were similar to those in 26 cases treated with daunorubicin (DNR) in our hospital according to JALSG-AML92. The outcome in cases with abnormal chromosomes and cases showing relapse was very poor. In particular, all 5 t(8;21) cases in our series relapsed, suggesting that t(8;21) cannot be considered a favorable prognostic factor in cases treated with IDR-containing regimens. However, 3 of the 5 t(8;21) cases were positive for CD56, which itself is an unfavorable prognostic factor. Thus it is possible that CD56 was related to the poor outcome. Intensive post-remission induction chemotherapies will be required in order to obtain prolonged disease-free survival.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 42 (1), 15-22, 2001

    The Japanese Society of Hematology

Citations (1)*help

See more

References(19)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top